Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00153933 · ClinicalTrials.gov registry record · Phase 1
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
NCT00153933 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 58 participants.
The verdict
NCT00153933, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose if this study is to evaluate the side effects of the combination of bortezomib and Revlimid (CC-5013) in patients with relapsed and relapsed/refractory multiple myeloma.
Interventions
- DRUG Bortezomib
- DRUG CC-5013
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2004-08 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00153933
The ClinicalTrials.gov registry entry for NCT00153933 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bortezomib is the first listed.
NCT00153933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00153933 about?
NCT00153933 is a clinical study titled "Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma". The purpose if this study is to evaluate the side effects of the combination of bortezomib and Revlimid (CC-5013) in patients with relapsed and relapsed/refractory multiple myeloma.
What is the current status of trial NCT00153933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2004-08. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00153933?
The interventions under investigation include: Bortezomib (DRUG), CC-5013 (DRUG).
Who is sponsoring clinical trial NCT00153933?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.